A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.

Syst Rev · 2018 · PMC6145118 · PMID 30227896

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

did not reach statistical significancep = 0.053so close (0.05 < p ≤ 0.1)

Outcomes Compared to BSC, azacitidine significantly reduced mortality (RR = 0.83, 95% CI 0.74–0.94, p = 0.002, I 2 = 89.3%) (Additional file 1 : Figure S1) whereas the effect of decitabine did not reach statistical significance (RR = 0.88, 95% CI 0.77–1.001, p = 0.053, I 2 = 53.0%) (Additional file 1 : Figure S2).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.